- Home
- SGC vs CRDF Comparison
SGC vs CRDF Comparison
Compare SGC & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGC
- CRDF
- Stock Information
- Founded
- SGC 1920
- CRDF 1999
- Country
- SGC United States
- CRDF United States
- Employees
- SGC N/A
- CRDF N/A
- Industry
- SGC Apparel
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SGC Consumer Discretionary
- CRDF Health Care
- Exchange
- SGC Nasdaq
- CRDF Nasdaq
- Market Cap
- SGC 281.4M
- CRDF 288.7M
- IPO Year
- SGC N/A
- CRDF N/A
- Fundamental
- Price
- SGC $11.67
- CRDF $4.00
- Analyst Decision
- SGC Strong Buy
- CRDF Strong Buy
- Analyst Count
- SGC 2
- CRDF 4
- Target Price
- SGC $19.00
- CRDF $12.00
- AVG Volume (30 Days)
- SGC 50.1K
- CRDF 1.2M
- Earning Date
- SGC 03-11-2025
- CRDF 05-01-2025
- Dividend Yield
- SGC 4.97%
- CRDF N/A
- EPS Growth
- SGC 35.19
- CRDF N/A
- EPS
- SGC 0.73
- CRDF N/A
- Revenue
- SGC $565,676,000.00
- CRDF $683,000.00
- Revenue This Year
- SGC $5.04
- CRDF N/A
- Revenue Next Year
- SGC $5.54
- CRDF N/A
- P/E Ratio
- SGC $15.27
- CRDF N/A
- Revenue Growth
- SGC 4.12
- CRDF 39.96
- 52 Week Low
- SGC $10.90
- CRDF $2.01
- 52 Week High
- SGC $21.80
- CRDF $6.42
- Technical
- Relative Strength Index (RSI)
- SGC 26.41
- CRDF 48.99
- Support Level
- SGC $10.90
- CRDF $3.52
- Resistance Level
- SGC $14.46
- CRDF $4.42
- Average True Range (ATR)
- SGC 0.55
- CRDF 0.38
- MACD
- SGC -0.26
- CRDF -0.04
- Stochastic Oscillator
- SGC 18.73
- CRDF 44.44
About SGC Superior Group of Companies Inc.
Superior Group Of Companies Inc designs apparel products. The company's operating segment includes Branded Products; Healthcare Apparel and Contact Centers. It generates maximum revenue from the Branded Products segment. The Branded Products segment produce and sell customized merchandising solutions, promotional products and branded uniform programs to customers.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical program in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC").